(September 24, 2024, 12:07 PM EDT) -- WASHINGTON, D.C. — The U.S. Patent Trial and Appeal Board was correct to hold that a pharmaceutical company’s claims related to a prefilled syringe for eye diseases were unpatentable, a Federal Circuit U.S. Court of Appeal panel held Sept. 23, agreeing with the board that the claims are combinations of prior art references....